Medical Devices Startups

Arbor develops programmable DNA editors for genetic medicine, aiming to enable functional cures for patients by addressing genetic diseases through bespoke gene editing approaches. The company is developing a portfolio of DNA editing technologies capable of targeting over 90% of the human genome for therapeutic applications.

4 investors

ARS Pharma develops needle-free epinephrine treatments, including neffy, an FDA-approved epinephrine nasal spray for patients and caregivers managing allergic reactions. The company focuses on providing portable, easy-to-use alternatives to needle-based epinephrine delivery.

4 investors

AssistIQ uses AI-powered computer vision to automatically capture and recognize implants, tissue, and surgical supplies as they are used in the operating room, updating inventory and charge data without manual entry. It serves hospitals and health systems in the United States, integrating with EHR and ERP systems to improve billing accuracy, reduce waste, and support clinical documentation.

4 investors

Atara Biotherapeutics develops allogeneic T-cell immunotherapies using its proprietary EBV T-cell platform to harness the immune system for treating disease. The company focuses on next-generation cell-based therapies designed for patients worldwide.

4 investors

Atelerix develops hypothermic hydrogel encapsulation technology that stabilises and preserves fresh cells, tissues, and blood at room temperature, eliminating the need for cryopreservation and cold-chain logistics. Its plant-based, xeno-free kits (such as CytoStor, BeadReady, and STORganoid) serve research and clinical labs shipping live cell material, organoids, and 3D cell models.

4 investors

AvenCell Therapeutics develops next-generation cell therapies for hard-to-treat cancers, including solid tumors, combining switchable universal CAR-T technology with a CRISPR/Cas9-based allogeneic platform. The clinical-stage biopharmaceutical company creates autologous and allogeneic reprogrammable T-cell products and operates in both the US and Europe.

4 investors

Averna Therapeutics is a biotechnology company developing therapeutics. The page is a team bio profiling its CEO and board member.

4 investors

AVTTX is a clinical-stage company developing gene therapy treatments for retinal and ophthalmologic diseases. The company leverages adeno-associated virus (AAV) technology to address unmet medical needs in vision care.

4 investors

Axi.om uses agentic intelligence and AI to predict, explain, and fix drug toxicity early in development by leveraging the largest experimental-to-clinical dataset of profiled molecules linked to human clinical outcomes.

4 investors

Azafaros is a clinical-stage biopharmaceutical company developing nizubaglustat, an orally available azasugar with a dual mode of action targeting the central nervous system and glycosphingolipid metabolism. Its lead candidate is being evaluated in a Phase 3 study for treating patients with GM1/GM2 gangliosidoses and related rare lysosomal storage disorders.

4 investors

Basilard BioTech develops Celletto, a nanomechanical (mechanoporation) gene delivery platform that inserts genes directly into the nucleus of cells without viral vectors, aimed at cell and gene therapy (CGT) developers and manufacturers. The technology targets the gene-delivery bottleneck in engineering cell-based therapies, offering an alternative to viral, chemical, and physical delivery methods.

4 investors

Biocartis develops Idylla, a fully automated real-time PCR molecular testing system that delivers biomarker results in about three hours for oncology applications. The company targets clinical labs, oncologists, and pathologists, and runs partnership programs with pharmaceutical and diagnostic companies.

4 investors

BioIntelliSense develops scalable physiologic monitoring technology for continuous, proactive patient monitoring aimed at improving clinical outcomes and lowering the cost of care. Founded in 2019, the company builds medical monitoring solutions for healthcare providers and patients.

4 investors

Biolinq develops a non-invasive glucose sensor that uses light to display glucose levels in real time, while also tracking activity and sleep to provide personalized health insights via a mobile app.

4 investors

Bodyport develops an FDA-cleared cardiac scale that non-invasively measures hemodynamic biomarkers through a patient's feet to detect early signs of worsening heart failure in a home setting. The company's platform pairs this hardware with a proprietary algorithm called the Congestion Index and a software system that integrates with electronic health records to enable remote patient monitoring and clinical decision support for heart failure management.

4 investors

BRAINBox Solutions develops a multi-modality diagnostic approach for mild traumatic brain injury (mTBI), combining blood biomarker panels with tablet-based neurocognitive testing to produce an objective injury score and a prognosis of post-injury symptoms. The tools are aimed at clinicians for diagnosing concussion and predicting patient outcomes.

4 investors

C. Light Technologies develops eye-tracking technology for clinical applications, offering objective metrics to assess patient neurological and vision-related conditions. The company's FDA-approved Retitrack device detects fixational eye movements for use in diagnosing neurodegenerative diseases, brain injuries, and sports vision performance.

4 investors

Cadenza Bio develops small-molecule drugs for oral administration to treat demyelinating and inflammatory diseases. The company focuses on halting disease progression and promoting tissue repair in patients with debilitating conditions.

4 investors

CCG.ai develops software that uses clinical and genomic data to help oncologists select appropriate cancer treatments for individual patients, with a focus on identifying predictive biomarkers linked to treatment response.

4 investors

Canvas Medical develops a customizable and extensible electronic medical record (EMR) platform for ambulatory clinics, featuring developer tools, APIs, and AI capabilities like clinical co-pilots to automate workflows in scheduling, charting, and billing.

4 investors

AbbVie is a biopharmaceutical company that discovers and delivers medicines for immune-mediated diseases and other therapeutic areas globally.

4 investors

Carda Health provides at-home virtual cardiac and pulmonary rehabilitation for patients with conditions like COPD and heart disease, delivering physician-supervised care through clinical exercise physiologists with live vital-sign monitoring. The company ships patients a care kit and matches them with clinicians for personalized, remotely-supervised exercise, nutrition, and stress-management programs.

4 investors

Cardiac Insight develops handheld and wearable ECG devices for cardiac diagnostics, including the Cardea 20/20 for athlete heart screening and the Cardea SOLO for 7-day ambulatory monitoring. The company serves healthcare providers and patients seeking reliable electrocardiogram analysis and cardiac evaluation.

4 investors

Cardiologs develops software that uses clinically validated AI and cloud technology to analyze ECGs and support cardiology diagnostics. Its tools serve clinicians and service providers handling growing demand for cardiological diagnosis, including Holter monitoring.

4 investors